Radiomics Feature Activation Maps as a New Tool for Signature Interpretability.

computed tomography interpretability local radiomics lung cancer peritumoral radiomics radiomics activation maps

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 01 07 2020
accepted: 22 10 2020
entrez: 28 12 2020
pubmed: 29 12 2020
medline: 29 12 2020
Statut: epublish

Résumé

In the field of personalized medicine, radiomics has shown its potential to support treatment decisions. However, the limited feature interpretability hampers its introduction into the clinics. Here, we propose a new methodology to create radiomics feature activation maps, which allows to identify the spatial-anatomical locations responsible for signature activation based on local radiomics. The feasibility of this technique will be studied for histological subtype differentiation (adenocarcinoma Pre-treatment CT scans were collected from a multi-centric Swiss trial (training, n=73, IIIA/N2 NSCLC, SAKK 16/00) and an independent cohort (validation, n=32, IIIA/N2/IIIB NSCLC). Based on the gross tumor volume (GTV), four peritumoral region of interests (ROI) were defined: lung_exterior (expansion into the lung), iso_exterior (expansion into lung and soft tissue), gradient (GTV border region), GTV+Rim (GTV and iso_exterior). For each ROI, 154 radiomic features were extracted using an in-house developed software implementation (Z-Rad, Python v2.7.14). Features robust against delineation variability served as an input for a multivariate logistic regression analysis. Model performance was quantified using the area under the receiver operating characteristic curve (AUC) and verified using five-fold cross validation and internal validation. Local radiomic features were extracted from the GTV+Rim ROI using non-overlapping 3x3x3 voxel patches previously marked as GTV or rim. A binary activation map was created for each patient using the median global feature value from the training. The ratios of activated/non-activated patches of GTV and rim regions were compared between histological subtypes (Wilcoxon test). Iso_exterior, gradient, GTV+Rim showed good performances for histological subtype prediction (AUC In this exploratory study, radiomics-based prediction of NSCLC histological subtypes was predominantly based on the peritumoral region indicating that radiomics activation maps can be useful for tracing back the spatial location of regions responsible for signature activation.

Identifiants

pubmed: 33364192
doi: 10.3389/fonc.2020.578895
pmc: PMC7753181
doi:

Types de publication

Journal Article

Langues

eng

Pagination

578895

Informations de copyright

Copyright © 2020 Vuong, Tanadini-Lang, Wu, Marks, Unkelbach, Hillinger, Eboulet, Thierstein, Peters, Pless, Guckenberger and Bogowicz.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Radiology. 2016 Dec;281(3):947-957
pubmed: 27347764
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Med Phys. 2020 Sep;47(9):4045-4053
pubmed: 32395833
PLoS One. 2017 Sep 21;12(9):e0178524
pubmed: 28934225
Medicine (Baltimore). 2019 Jan;98(1):e13963
pubmed: 30608433
Acta Oncol. 2018 Aug;57(8):1070-1074
pubmed: 29513054
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):921-928
pubmed: 28807534
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Nat Rev Cancer. 2014 Aug;14(8):535-46
pubmed: 25056707
Front Oncol. 2016 Mar 30;6:71
pubmed: 27064691
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Q J Nucl Med Mol Imaging. 2019 Dec;63(4):355-370
pubmed: 31527578
Bioinformatics. 2011 Nov 15;27(22):3206-8
pubmed: 21903630
PLoS One. 2020 May 22;15(5):e0232639
pubmed: 32442178
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929
Acta Oncol. 2017 Nov;56(11):1544-1553
pubmed: 28885084
Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1015-24
pubmed: 11072158
Eur Radiol. 2012 Apr;22(4):796-802
pubmed: 22086561
Sci Rep. 2015 Jun 05;5:11044
pubmed: 26251068
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Br J Radiol. 2018 Jun;91(1086):20170498
pubmed: 29451412
Respirology. 2011 Nov;16(8):1210-20
pubmed: 21801275
Med Phys. 2019 Oct;46(10):4545-4552
pubmed: 31376283
Sci Rep. 2017 Aug 11;7(1):7952
pubmed: 28801575
Eur Radiol. 2018 Jul;28(7):2772-2778
pubmed: 29450713
Sci Rep. 2016 Sep 20;6:33860
pubmed: 27645803
Philos Trans A Math Phys Eng Sci. 2016 Apr 13;374(2065):20150202
pubmed: 26953178
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Phys Med Biol. 2018 Nov 08;63(22):225003
pubmed: 30272571
Eur J Cancer. 2012 Mar;48(4):441-6
pubmed: 22257792
Sci Rep. 2018 Aug 29;8(1):13047
pubmed: 30158540
Clin Lung Cancer. 2016 Sep;17(5):441-448.e6
pubmed: 27017476
Radiother Oncol. 2015 Mar;114(3):345-50
pubmed: 25746350
Radiother Oncol. 2016 Jun;119(3):480-6
pubmed: 27085484
Comput Methods Programs Biomed. 2018 Jun;159:23-30
pubmed: 29650315
Med Phys. 2019 Nov;46(11):5075-5085
pubmed: 31494946
Clin Cancer Res. 2020 May 1;26(9):2151-2162
pubmed: 32198149
Lung Cancer. 2018 Jan;115:34-41
pubmed: 29290259
Transl Oncol. 2015 Dec;8(6):524-34
pubmed: 26692535
Cancer Res. 2017 Jul 15;77(14):3922-3930
pubmed: 28566328
J Thorac Oncol. 2017 Mar;12(3):467-476
pubmed: 27903462
J Comput Assist Tomogr. 2019 Mar/Apr;43(2):300-306
pubmed: 30664116

Auteurs

Diem Vuong (D)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Stephanie Tanadini-Lang (S)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Ze Wu (Z)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Robert Marks (R)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Jan Unkelbach (J)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Sven Hillinger (S)

Department of Thoracic Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Eric Innocents Eboulet (EI)

Department of Clinical Trial Management, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.

Sandra Thierstein (S)

Department of Clinical Trial Management, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.

Solange Peters (S)

Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Miklos Pless (M)

Department of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.

Matthias Guckenberger (M)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Marta Bogowicz (M)

Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Classifications MeSH